Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 as an Early Biomarker for ST Elevation Myocardial Infarction : Time-Dependent Comparison With Other Biomarkers

Access this Article

Search this Article

Author(s)

    • KOBAYASHI Nobuaki
    • Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
    • HATA Noritake
    • Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
    • KUME Noriaki
    • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
    • SEINO Yoshihiko
    • Department of Internal Medicine, Chiba Hokusoh Hospital, Nippon Medical School
    • INAMI Toru
    • Department of Internal Medicine, Chiba Hokusoh Hospital, Nippon Medical School
    • YOKOYAMA Shinya
    • Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
    • SHINADA Takuro
    • Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
    • TOMITA Kazunori
    • Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
    • MIZUNO Kyoichi
    • Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine, Department of Internal Medicine, Nippon Medical School

Abstract

<b><i>Background:</i></b> The diagnostic sensitivity of myocardial necrosis markers, such as creatine kinase-MB (CK-MB), cardiac troponins, myoglobin and heart-type fatty acid-binding protein (H-FABP) for the earliest stage of ST-elevation myocardial infarction (STEMI), remains insufficient. We compared a new biomarker of plaque vulnerability (soluble lectin-like oxidized low-density lipoprotein receptor-1, sLOX-1) with other biomarkers at the earliest stage of STEMI. <b><i>Methods and Results:</i></b> Plasma sLOX-1 levels were measured in 125 STEMI, 44 non-STEMI (NSTEMI) and 125 non-acute myocardial infarction (non-AMI) patients and were significantly (P<0.0001) higher in the STEMI and NSTEMI than in the non-AMI patients (median, 25th and 75th percentiles: 241.0, 132.3 and 472.2 vs. 147.3, 92.9 and 262.4 vs. 64.3, 54.4 and 84.3pg/ml, respectively). At the optimal cut-off value of 91.0pg/ml, sLOX-1 discriminated STEMI from non-AMI with 89.6% sensitivity and 82.4% specificity. Time-dependent changes in sLOX-1, H-FABP, myoglobin, troponin T and CK-MB were analyzed in 27 STEMI patients. Elevated plasma sLOX-1 levels persisted for 24h after admission, whereas other markers were not elevated at the time of admission and peaked at ≥2h thereafter. The diagnostic sensitivity of sLOX-1, H-FABP, myoglobin, troponin T and CK-MB for STEMI upon admission (89min after onset) was 93%, 78%, 70%, 56% and 33%, respectively. <b><i>Conclusions:</i></b> Plasma sLOX-1 diagnosed the early stages of STEMI more accurately than H-FABP, myoglobin, troponin T and CK-MB. (<i>Circ J</i> 2011; <b>75:</b> 1433-1439)<br>

Journal

  • Circulation Journal

    Circulation Journal 75(6), 1433-1439, 2011-05-25

    The Japanese Circulation Society

References:  36

Cited by:  7

Codes

  • NII Article ID (NAID)
    10028149040
  • NII NACSIS-CAT ID (NCID)
    AA11591968
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    13469843
  • DOI
    10.1253/circj.CJ-10-0913
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top